

# Kadoaki Ohashi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4875656/publications.pdf>

Version: 2024-02-01

131  
papers

5,069  
citations

279487

23  
h-index

91712

69  
g-index

132  
all docs

132  
docs citations

132  
times ranked

8205  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>HER2</i> Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in <i>EGFR</i> -Mutant Lung Cancers That Lack the Second-Site <i>EGFR</i> T790M Mutation. <i>Cancer Discovery</i> , 2012, 2, 922-933.	7.7	613
2	Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC. <i>Cancer Discovery</i> , 2013, 3, 1404-1415.	7.7	564
3	Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i> -Amplified Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 944-957.	13.9	542
4	Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 813-824.	13.9	505
5	Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling. <i>Science Translational Medicine</i> , 2011, 3, 90ra59.	5.8	457
6	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Disease. <i>Journal of Clinical Oncology</i> , 2013, 31, 1070-1080.	0.8	425
7	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS</i> , <i>NRAS</i> , or <i>MEK1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2127-33.	3.3	410
8	Characteristics of Lung Cancers Harboring <i>NRAS</i> Mutations. <i>Clinical Cancer Research</i> , 2013, 19, 2584-2591.	3.2	134
9	A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 273-279.	0.5	119
10	Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. <i>Cancer Research</i> , 2016, 76, 1506-1516.	0.4	115
11	Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation <i>In vivo</i> . <i>Cancer Research</i> , 2009, 69, 5091-5098.	0.4	65
12	Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. <i>Lung Cancer</i> , 2006, 53, 117-121.	0.9	56
13	Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. <i>Genome Research</i> , 2013, 23, 1434-1445.	2.4	48
14	The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 762-765.	0.6	43
15	<i>JAK</i> -related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation. <i>Cancer Science</i> , 2012, 103, 1795-1802.	1.7	40
16	Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model. <i>Cancer Science</i> , 2013, 104, 1440-1446.	1.7	34
17	<i>MET</i> or <i>NRAS</i> amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. <i>Scientific Reports</i> , 2018, 8, 1955.	1.6	34
18	<i>NF-<math>\kappa</math>B</i> drives acquired resistance to a novel mutant-selective EGFR inhibitor. <i>Oncotarget</i> , 2015, 6, 42717-42732.	0.8	31

#	ARTICLE	IF	CITATIONS
19	Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study. <i>Cancer Medicine</i> , 2020, 9, 6597-6608.	1.3	30
20	MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. <i>Nature Communications</i> , 2021, 12, 5505.	5.8	30
21	VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small cell lung cancers. <i>Cancer Science</i> , 2021, 112, 1853-1864.	1.7	29
22	Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2020, 59, 249-256.	0.8	28
23	Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 29525-29531.	0.8	28
24	Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP1 promoter. <i>Cancer Science</i> , 2008, 99, 1747-1753.	1.7	27
25	Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. <i>Experimental Cell Research</i> , 2013, 319, 417-423.	1.2	25
26	A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404. <i>Lung Cancer</i> , 2018, 115, 103-108.	0.9	25
27	A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY). <i>Chest</i> , 2019, 156, 357-366.	0.4	25
28	Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice. <i>Cancer Research</i> , 2009, 69, 7088-7095.	0.4	23
29	Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2009-2018.	0.5	22
30	Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. <i>Cancer Science</i> , 2018, 109, 3149-3158.	1.7	20
31	STAT3 expression in activating EGFR-driven adenocarcinoma of the lung. <i>Lung Cancer</i> , 2012, 75, 24-29.	0.9	19
32	Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol. <i>Clinical Lung Cancer</i> , 2017, 18, 92-95.	1.1	19
33	Endobronchial ultrasound-guided transbronchial biopsy with or without a guide sheath for diagnosis of lung Cancer. <i>Respiratory Investigation</i> , 2015, 53, 93-97.	0.9	18
34	Safety and discomfort during bronchoscopy performed under sedation with fentanyl and midazolam: a prospective study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 871-874.	0.6	17
35	Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 458-464.	0.6	17
36	The effect of nivolumab treatment for central nervous system metastases in non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, e20601-e20601.	0.8	17

#	ARTICLE	IF	CITATIONS
37	Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0121211.	1.1	16
38	Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 360-367.	1.0	15
39	Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 54-58.	0.9	15
40	Downregulation of TBXAS 1 in an iron-induced malignant mesothelioma model. <i>Cancer Science</i> , 2015, 106, 1296-1302.	1.7	14
41	Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M. <i>Molecular Oncology</i> , 2017, 11, 670-681.	2.1	14
42	Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1447-1453.	0.6	14
43	Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET). <i>Translational Lung Cancer Research</i> , 2021, 10, 314-325.	1.3	13
44	A New Target for Therapy in Squamous Cell Carcinoma of the Lung: Table 1.. <i>Cancer Discovery</i> , 2011, 1, 23-24.	7.7	12
45	Optimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR system. <i>Oncology Reports</i> , 2017, 37, 3100-3106.	1.2	12
46	Pilot evaluation of a HER2 testing in non-small-cell lung cancer. <i>Journal of Clinical Pathology</i> , 2020, 73, 353-357.	1.0	12
47	Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET amplified advanced NSCLC: GEOMETRY mono-1 study. <i>Cancer Science</i> , 2021, 112, 1556-1566.	1.7	12
48	Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9509-9509.	0.8	12
49	Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). <i>Clinical Lung Cancer</i> , 2016, 17, 602-605.	1.1	10
50	Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations. <i>Biochemical and Biophysical Research Communications</i> , 2020, 532, 341-346.	1.0	10
51	Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS-mutated non-small cell lung cancer (NSCLC): A result of nationwide genomic screening project (LC-SCRUM-Japan).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9589-9589.	0.8	10
52	CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in EGFR-Mutant Lung Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 1111-1126.	1.6	10
53	Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice. <i>Lung Cancer</i> , 2009, 65, 284-289.	0.9	9
54	Long-term spontaneous remission with active surveillance in IgG4-related pleuritis: A case report and literature review. <i>Respiratory Medicine Case Reports</i> , 2019, 28, 100938.	0.2	9

#	ARTICLE	IF	CITATIONS
55	Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review. <i>Internal Medicine</i> , 2020, 59, 823-828.	0.3	9
56	Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis. <i>Lung Cancer</i> , 2020, 150, 83-89.	0.9	9
57	Identification of targetable kinases in idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2022, 23, 20.	1.4	8
58	A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages. <i>Internal Medicine</i> , 2019, 58, 3033-3037.	0.3	7
59	EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice. <i>Lung Cancer</i> , 2019, 136, 86-93.	0.9	7
60	Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 101-108.	0.7	7
61	A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1+ lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1/TP53 mutations. <i>Lung Cancer</i> , 2021, 156, 1-4.	0.9	7
62	SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non-small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1653-1662.	1.9	7
63	Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1269-1276.	0.6	7
64	Ruptured Littoral Cell Angiosarcoma Causing Hemoperitoneum. <i>Internal Medicine</i> , 2012, 51, 337-338.	0.3	6
65	Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors. <i>Experimental Cell Research</i> , 2014, 326, 201-209.	1.2	6
66	Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 941-947.	1.1	6
67	Discomfort during bronchoscopy performed after endobronchial intubation with fentanyl and midazolam: a prospective study. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 434-437.	0.6	6
68	Osimertinib Depletes EGFR-T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M. <i>Journal of Thoracic Oncology</i> , 2018, 13, e140-e142.	0.5	6
69	Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study. <i>Trials</i> , 2020, 21, 298.	0.7	6
70	A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 956-965.	0.6	6
71	Abstract 2101A: CNX-2006, a novel irreversible epidermal growth factor receptor (EGFR) inhibitor, selectively inhibits EGFR T790M and fails to induce T790M-mediated resistance <i>in vitro</i> . <i>Cancer Research</i> , 2013, 73, 2101A-2101A.	0.4	6
72	A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202. <i>Lung Cancer</i> , 2017, 112, 188-194.	0.9	5

#	ARTICLE	IF	CITATIONS
73	Abstract 2131: Significant combination benefit of anti-VEGFR antibody and oncogene-targeted agents in EGFR or ALK mutant NSCLC cells. , 2019, , .		5
74	Contribution of nationwide genome screening in Japan (LC-SCRUM-Japan) to the development of precision medicine for non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, 9085-9085.	0.8	5
75	Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells. Oncology Reports, 2007, 17, 983.	1.2	4
76	Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation. OncoTargets and Therapy, 2016, 9, 1753.	1.0	4
77	Detection of epidermal growth factor receptor mutations in exhaled breath condensate using droplet digital polymerase chain reaction. Oncology Letters, 2020, 20, 1-1.	0.8	4
78	Abstract 5198: Combination effect of anti-VEGFR-2 antibody with erlotinib on EGFR mutant non-small cell lung cancer. Cancer Research, 2016, 76, 5198-5198.	0.4	4
79	Randomized Phase II Study Comparing Mannitol with Furosemide for the Prevention of Renal Toxicity Induced by Cisplatin-based Chemotherapy with Short-term Low-volume Hydration in Advanced Non-small Cell Lung Cancer: The OLCSG1406 Study Protocol. Acta Medica Okayama, 2018, 72, 319-323.	0.1	4
80	Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery. Japanese Journal of Clinical Oncology, 2018, 48, 287-290.	0.6	3
81	Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutation with a History of Acquired Resistance to Osimertinib. Internal Medicine, 2019, 58, 1625-1627.	0.3	3
82	A phase I/II trial of weekly nabâ€paclitaxel for pretreated nonâ€smallâ€cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 250-256.	0.7	3
83	Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients. Respiratory Investigation, 2021, 59, 240-246.	0.9	3
84	Tumor agnostic efficacy of selpercatinib in patients with <i>RET</i> fusion+ solid tumors: A global, multicenter, registrational trial update (LIBRETTO-001).. Journal of Clinical Oncology, 2022, 40, 3094-3094.	0.8	3
85	Radiation Necrosis Mimicking Progressive Brain Metastasis in a Patient with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 762-763.	0.5	2
86	Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on<sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography. Japanese Journal of Clinical Oncology, 2016, 46, 529-533.	0.6	2
87	Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies. Respiratory Investigation, 2019, 57, 460-465.	0.9	2
88	Patientsâ€™ preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406. Acta OncolÃ³gica, 2020, 59, 324-328.	0.8	2
89	The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, e21147-e21147.	0.8	2
90	Large scale clinico-genomic analyses among patients with BRAF-mutated non-small cell lung cancers (NSCLC) identified by nationwide genomic screening project (LC-SCRUM-Japan).. Journal of Clinical Oncology, 2020, 38, 9590-9590.	0.8	2

#	ARTICLE	IF	CITATIONS
91	Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies. Acta Medica Okayama, 2020, 74, 371-379.	0.1	2
92	Deciphering the clinical features of heterogeneous stage III non-small cell lung cancer in Japanese real-world clinical practice: Expanded cohort of the SOLUTION study. Lung Cancer, 2022, 165, 152-163.	0.9	2
93	Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan. Internal Medicine, 2022, 61, 379-383.	0.3	1
94	Phase II study of brigatinib in ROS1 positive non-small cell lung cancer (NSCLC) patients previously treated with crizotinib: Barossa cohort 2.. Journal of Clinical Oncology, 2021, 39, 9040-9040.	0.8	1
95	Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR mutant lung cancer with HIF1 $\alpha$ /TGF $\beta$ expression. Oncology Letters, 2021, 22, 639.	0.8	1
96	Abstract 4487: Effect of everolimus on lung tumorigenesis in transgenic mice carrying activating EGFR mutation. , 2011, , .		1
97	Abstract 1897:RAS signaling pathway gene mutations and acquired resistance to EGFR tyrosine-kinase inhibitors in EGFR mutant lung cancer. , 2012, , .		1
98	Abstract 1368: The impact of bevacizumab on combination low-dose afatinib and cetuximab therapy in lung cancer cells harboring activated EGFR mutations. , 2015, , .		1
99	Abstract 3164: A comprehensive analysis of autopsied specimens and patient-derived cell lines in ALK-positive lung cancers with rapid acquired resistance to alectinib. , 2017, , .		1
100	Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis.. Journal of Clinical Oncology, 2019, 37, 9056-9056.	0.8	1
101	Randomized phase II study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in advanced non-small cell lung cancer: The OLCSG1406 trial.. Journal of Clinical Oncology, 2019, 37, e23105-e23105.	0.8	1
102	A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed after standard chemotherapy, or were primarily refractory to standard chemotherapy. Okayama Igakkai Zasshi, 2015, 127, 127-132.	0.0	1
103	Development of nationwide genomic screening project (LC-SCRUM-Japan) contributing to the establishment of precision medicine in Japan.. Journal of Clinical Oncology, 2016, 34, 9089-9089.	0.8	1
104	Abstract 3152: Acquired resistance to the third-generation EGFR inhibitor ASP8273 is associated with MET or NRAS gene amplifications in preclinical models. , 2017, , .		1
105	Abstract 1160: The novel osimertinib resistant lung cancer mice model harboring EGFR mutations driven by the SP-C promoter. , 2018, , .		1
106	Abstract 582: Tumor immunoediting in a lung cancer mouse model harboring EGFR mutations. , 2019, , .		1
107	Transformation to Small-Cell Lung Cancer Following Treatment with Vandetanib in a Patient with Lung Adenocarcinoma. Annals of Oncology, 2014, 25, v89.	0.6	0
108	A case of axillary lymphadenitis caused by Mycobacterium intracellulare in an immunocompetent patient. Respiratory Medicine Case Reports, 2019, 28, 100947.	0.2	0



#	ARTICLE	IF	CITATIONS
109	Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group.. Journal of Clinical Oncology, 2021, 39, e20590-e20590.	0.8	0
110	MO19-2 INSIGHT2: Tepotinib + osimertinib in pts with EGFR-mutant NSCLC and acquired resistance to 1L osimertinib due to METamp. Annals of Oncology, 2021, 32, S309.	0.6	0
111	Abstract 717: JAK2/STAT3 induces erlotinib-resistance in lung cancer cells harboring EGFR-activating mutations. , 2011, , .		0
112	Abstract 724: Role of ERK reactivation mediated by Src in acquired resistance to gefitinib in non-small cell lung cancer with EGFR mutation. , 2011, , .		0
113	Abstract 3681: Vascular endothelial growth factor receptor tyrosine kinase inhibitor inhibited mutated epidermal growth factor receptor-driven tumors ex vivo and in vivo. , 2011, , .		0
114	Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer. Clinical Cancer Research, 2012, 18, A23-A23.	3.2	0
115	Time trend in the survival advantage in phase III trials investigating molecular-targeted agents for advanced non-small cell lung cancer (NSCLC) during the past decade.. Journal of Clinical Oncology, 2014, 32, e19084-e19084.	0.8	0
116	Abstract 5248: Non-invasive EGFR T790M detection using droplet digital PCR system. , 2015, , .		0
117	Development of a nationwide genomic screening network for squamous cell lung cancer in Japan (LC-SCRUM-Japan).. Journal of Clinical Oncology, 2016, 34, 9097-9097.	0.8	0
118	Second primary cancer in survivors of locally advanced NSCLC treated with concurrent chemoradiation followed by surgery.. Journal of Clinical Oncology, 2016, 34, 10100-10100.	0.8	0
119	Association with consolidation chemotherapy after concurrent chemoradiotherapy followed by surgery and the disease free survival in patients with stage III non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, e20053-e20053.	0.8	0
120	Abstract 4667: pCR induced by triplet therapy with low-dose afatinib, cetuximab and bevcizumab in lung cancer cells harboring EGFR T790M. , 2016, , .		0
121	Abstract 1889: AXL and EGFR signaling mediate resistance to Crizotinib in non-small cell lung cancer cells harboring the ROS1 fusion gene. , 2016, , .		0
122	Abstract 2103: Activating alternative receptor tyrosine kinases induced alectinib-resistance in ALK rearranged non-small cell lung cancer cells. , 2016, , .		0
123	Abstract 2249: Detection of EGFR mutations in circulating cell-free DNA of non-small cell lung cancer patients by next-generation sequencing. , 2016, , .		0
124	Chemoradiotherapy (CRT) for locally-advanced (LA) lung cancer patients with interstitial lung abnormalities (ILA).. Journal of Clinical Oncology, 2017, 35, e20057-e20057.	0.8	0
125	Contribution to the development of precision medicine and clinical utility of nationwide lung cancer genomic screening in Japan (LC-SCRUM-Japan).. Journal of Clinical Oncology, 2017, 35, e20659-e20659.	0.8	0
126	Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients.. Journal of Clinical Oncology, 2018, 36, e21034-e21034.	0.8	0



#	ARTICLE	IF	CITATIONS
127	Abstract 4818: In vivo efficacy of triplet therapy with osimertinib, cetuximab and bevacizumab for lung cancer cells harboring EGFR T790M. , 2018, , .		0
128	Tumor microenvironment affecting the effect of immuno-checkpoint inhibitors. Okayama Igakkai Zasshi, 2019, 131, 51-53.	0.0	0
129	Abstract 752: Rapid acquired resistance to alectinib in ALK-positive lung cancers with high tumor mutation burden. , 2019, , .		0
130	Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation. Acta Medica Okayama, 2016, 70, 243-53.	0.1	0
131	Preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: An open-label, randomized, phase II study.. Journal of Clinical Oncology, 2022, 40, TPS12141-TPS12141.	0.8	0